Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Short cationic antimicrobial peptides display superior antifungal activities toward Candidiasis and Onychomycosis in comparison with Terbinafine and Amorolfine
Show others and affiliations
2016 (English)In: Molecular Pharmaceutics, ISSN 1543-8384, E-ISSN 1543-8392Article in journal (Refereed) Epub ahead of print
Abstract [en]

Novel antifungals are in high demand due to the challenges associated with resistant, persistent, and systemic fungal infections. Synthetic mimics of antimicrobial peptides are emerging as a promising class of compounds for antifungal treatment. In the current study, five synthetic cationic antimicrobial tripeptides were evaluated as antifungal therapeutics against 24 pathogenic strains of fungi. Three of the peptides displayed strong general antifungal properties at low micromolar inhibitory concentrations. The most promising peptide, compound 5, was selected and evaluated as an antifungal remedy for Candida albicans candidiasis in a human skin model and for the treatment of Trichophyton rubrum induced onychomycosis in an infected human nail model. Compound 5 was shown to display antifungal properties and a rapid mode of action superior to those of both the commercial comparators Loceryl and Lamisil. Compound 5 was also active against a clinical isolate of Candida albicans with acquired fluconazole resistance.

Place, publisher, year, edition, pages
American Chemical Society (ACS), 2016.
Keyword [en]
onychomycosis, candidiasis, antimicrobial peptides, terbinafine, amorolfine, antifungal
National Category
Pharmaceutical Sciences Infectious Medicine Microbiology in the medical area
Identifiers
URN: urn:nbn:se:ri:diva-13619DOI: 10.1021/acs.molpharmaceut.6b00654OAI: oai:DiVA.org:ri-13619DiVA: diva2:1010098
Available from: 2016-09-30 Created: 2016-09-30 Last updated: 2017-01-06Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full texthttp://dx.doi.org/10.1021/acs.molpharmaceut.6b00654
By organisation
Medicinteknik
In the same journal
Molecular Pharmaceutics
Pharmaceutical SciencesInfectious MedicineMicrobiology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 10 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
v. 2.27.0